ChronicleBio Appoints Immunology Pioneer John Mumm as CSO to Decode Neuroimmune Disorders with Multi-Omic Precision Platform
核心洞察
ChronicleBio (搜索) appointed Dr. John Mumm, a three-decade immunology innovator and former Deka Biosciences (搜索) CEO, as Chief Scientific Officer to lead its neuroimmune disease pipeline.
Mumm joins Head of Platform Dr. Yambazi Banda to build a multi-omic endotype framework integrating genomics, proteomics, and AI to stratify patients by disease mechanism.
The company targets historically neglected neuroimmune conditions including ME/CFS (搜索), Long COVID (搜索), and POTS (搜索), which affect millions of patients worldwide.
ChronicleBio (搜索), a San Francisco-based data-driven techbio company, announced on June 11, 2026, the appointment of John Mumm, Ph.D., as Chief Scientific Officer. Mumm, a three-decade immunology innovator, serial founder, and author of more than 30 peer-reviewed publications, joins Head of Platform Yambazi Banda, Ph.D., to form the scientific leadership core of a startup aiming to end trial-and-error medicine for millions of patients with neuroimmune conditions.
"My time in immuno-oncology and autoimmunity taught me that 'one disease' is almost always three or four mechanistically distinct diseases sharing a clinical label, and that the right biomarker turns a 20% response rate into a 70% response rate. I'm bringing that same stratification playbook to neuroimmune disorders," Mumm said.
A Track Record in Precision Immunology
Mumm brings to ChronicleBio (搜索) extensive experience at the intersection of cytokine biology, immunology, and precision medicine. He is the founder and former CEO of Deka Biosciences (搜索), where he created the Diakine™ platform — engineered dual-cytokine therapeutics designed to precisely modulate immune responses in cancer and inflammatory disease. Under his leadership, Deka advanced from inception to FDA clearance for a Phase 1 clinical trial within 18 months of a Series A financing and completed a 39-patient basket trial in 12 months.
Mumm is also a founding member of ARMO BioSciences (搜索), which was acquired by Eli Lilly for $1.6 billion in 2018, where he played a central role in developing pegylated IL-10 (搜索) (AM0010), a first-in-class immunotherapy. His earlier roles at Merck Research Labs (搜索), MedImmune, and Schering-Plough (搜索) span CAR-T development, inflammasome-based neoantigen screening, and novel cytokine-based therapeutics.
The Multi-Omic Endotype Framework
ChronicleBio (搜索) was built on the premise that the defining failure mode in chronic disease research is the absence of mechanism-anchored patient stratification. Without it, the company argues, clinical trials are designed to fail as responders and non-responders cancel each other out. The company's multi-omic endotype framework addresses this directly by integrating whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, and metabolomics to identify biologically coherent patient subgroups before treatment begins.
The goal is to determine which therapy is most likely to work for which patient and which clinical-stage drugs might be repurposed for those whom the current standard of care fails, disrupting what the company describes as a historically ineffective therapeutic pipeline.
"There is a gap between what's possible and what has been done that we aim to fill. The system has effectively given up on millions of patients because their syndromes have long been thought to be too complex to take on, but we know they are actually tractable molecular problems we can solve with the right therapeutic targets," Mumm said.
Building the Platform Foundation
Banda, a Rhodes Scholar holding a D.Phil. in Particle Physics from Oxford, has spent the past year laying the scientific and technology foundation for ChronicleBio (搜索). His career spans postdoctoral research at UCSF, senior roles at Ancestry.com leading population genetics algorithm development and FDA 510(k) statistical submissions, and a directorship at Ambys Medicines (搜索) overseeing NGS pipeline development in the gene and cell therapy space.
Banda previously served as Executive Director of Spectrum Biobank, a non-profit dedicated to closing the genetic data diversity gap, and brings that commitment to equity and scientific inclusivity to ChronicleBio (搜索)'s biobank operations and external partnerships.
"I have conducted research in various fields of science from particle physics to statistical genetics and computational biology with the goal of helping answer some of humanity's pressing questions. The work being done at ChronicleBio (搜索), however, inspires me in a way that I have not been before," Banda said.
"When you combine fast-paced technology, both compute infrastructure and algorithms development, with a highly invested group of individuals, barriers to success diminish quickly. What we've managed to build at ChronicleBio (搜索) in only one year is evidence of genuine dedication to help find health solutions," Banda added.
Targeting Neglected Neuroimmune Conditions
ChronicleBio (搜索) focuses on neuroimmune conditions such as ME/CFS (搜索), Long COVID (搜索), and POTS (搜索) — diseases that the company notes have long been written off as idiopathic or incurable. What unites Mumm and Banda is a shared conviction that the chronic disease crisis, which affects hundreds of millions of patients worldwide, is a solvable biological problem that has simply not been attacked with the right tools.
"The team treats every patient sample as a falsifiable hypothesis rather than a data point," Mumm said. "That intellectual honesty is rare, and it's the only mindset that actually moves potential treatments for chronic disease forward."
ChronicleBio (搜索)'s platform integrates biobanking, advanced computational biology, and translational science to stratify patients by disease mechanism, enabling the development of precision diagnostics and therapeutic strategies for neuroimmune conditions.